arrow_back Trending Legislation
Share share

This act aims to lower drug prices by prohibiting unfair market practices.

This act aims to prevent pharmaceutical companies from engaging in practices that hinder the introduction of cheaper generic and biosimilar drugs. This means citizens can expect greater availability of more affordable medications, positively impacting their personal finances and access to healthcare. The Federal Trade Commission will have new tools to combat such actions.
Key points
Prohibits drug manufacturers' practices that block competition from cheaper alternatives.
Aims to increase the availability of more affordable generic and biosimilar drugs.
Strengthens the Federal Trade Commission's powers to prosecute unfair practices in the pharmaceutical market.
May lead to lower healthcare costs for citizens.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Print number: HR 2873
Sponsor: Rep. Cicilline, David N. [D-RI-1]
Process start date: 2021-04-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about This act aims to lower drug prices by prohibiting unfair market practices.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 2873.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Prohibits drug manufacturers' practices that block competition from cheaper alternatives.
  • Aims to increase the availability of more affordable generic and biosimilar drugs.
  • Strengthens the Federal Trade Commission's powers to prosecute unfair practices in the pharmaceutical market.
  • May lead to lower healthcare costs for citizens.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Cicilline, David N. [D-RI-1].

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 27 - 16.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HR 2873

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law Economy